{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:10:15Z","timestamp":1793945415111,"version":"4.8.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113731","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:19:14Z","timestamp":1744478354000},"page":"113731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cancer nanomedicine from a clinician-scientist perspective: Lessons and prospects"],"prefix":"10.1016","volume":"382","author":[{"given":"Alberto A.","family":"Gabizon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0005","first-page":"145","article-title":"E-rosettes in human lymphocytes. Enhancement and depression after incubation of lymphocytes with papain and trypsin","volume":"31","author":"Garrido","year":"1975","journal-title":"Rev. Esp. Fisiol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1979.tb47093.x","article-title":"Biochemical and biological properties of THF in animal and human models","volume":"332","author":"Trainin","year":"1979","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-065X.1971.tb00461.x","article-title":"Immunological surveillance in neoplasia","volume":"7","author":"Burnet","year":"1971","journal-title":"Immunol. Rev."},{"issue":"4031","key":"10.1016\/j.jconrel.2025.113731_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1126\/science.176.4031.170","article-title":"The immune reaction as a stimulator of tumor growth","volume":"176","author":"Prehn","year":"1972","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113731_bb0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.2910180613","article-title":"Kinetics of the response of spleen cells from tumor-bearing animals in an in vivo tumor neutralization assay","volume":"18","author":"Gabizon","year":"1976","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.1980.279","article-title":"Enhancement of growth of a radiation-induced lymphoma by T cells from normal mice","volume":"42","author":"Gabizon","year":"1980","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113731_bb0035","first-page":"913","article-title":"Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo","volume":"65","author":"Gabizon","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113731_bb0040","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00262-010-0893-2","article-title":"The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible \u201chard\u201d lesions","volume":"59","author":"Garrido","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113731_bb0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113731_bb0050","first-page":"873","article-title":"Clinical spectrum of anthracycline antibiotic cardiotoxicity","volume":"62","author":"Bristow","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"13","key":"10.1016\/j.jconrel.2025.113731_bb0055","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJM197609232951305","article-title":"The carrier potential of liposomes in biology and medicine (first of two parts)","volume":"295","author":"Gregoriadis","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jconrel.2025.113731_bb0060","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM197609302951406","article-title":"The carrier potential of liposomes in biology and medicine (second of two parts)","volume":"295","author":"Gregoriadis","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113731_bb0065","first-page":"2814","article-title":"Diffusion and convection in normal and neoplastic tissues","volume":"34","author":"Swabb","year":"1974","journal-title":"Cancer Res."},{"issue":"12 Pt 1","key":"10.1016\/j.jconrel.2025.113731_bb0070","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113731_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-230X(08)60946-X","article-title":"Tumor angiogenesis","volume":"43","author":"Folkman","year":"1985","journal-title":"Adv. Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113731_bb0080","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113731_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"17","key":"10.1016\/j.jconrel.2025.113731_bb0090","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030389","article-title":"Approaches to improve EPR-based drug delivery for Cancer therapy and diagnosis","volume":"13","author":"Subhan","year":"2023","journal-title":"J. Pers Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","article-title":"Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models","volume":"10","author":"Gabizon","year":"2002","journal-title":"J. Drug Target."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113731_bb0105","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s44222-024-00203-3","article-title":"Nanoparticle delivery to Tumours: from EPR and ATR mechanisms to clinical impact","volume":"2","author":"Dasgupta","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.jconrel.2025.113731_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-025-01877-5","article-title":"The pathways for nanoparticle transport across tumour endothelium","author":"Wu","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"23","key":"10.1016\/j.jconrel.2025.113731_bb0120","first-page":"255","article-title":"Model systems for cardiotoxic effects of anthracyclines","volume":"1978","author":"Zbinden","year":"1971","journal-title":"Antibiot. Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113731_bb0125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0006-291X(76)90838-X","article-title":"Affinity of adriamycin to phospholipids a possible explanation for cardiac mitochondrial lesions","volume":"71","author":"Duarte-Karim","year":"1976","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0006-291X(82)91976-3","article-title":"Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment","volume":"104","author":"Goormaghtigh","year":"1982","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8361","key":"10.1016\/j.jconrel.2025.113731_bb0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"2","author":"Harris","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113731_bb0140","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.1991.476","article-title":"Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin","volume":"64","author":"Gabizon","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113731_bb0145","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/0277-5379(89)90350-7","article-title":"Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study","volume":"25","author":"Gabizon","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"18","key":"10.1016\/j.jconrel.2025.113731_bb0150","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1073\/pnas.85.18.6949","article-title":"Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors","volume":"85","author":"Gabizon","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2025.113731_bb0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/08982108809035986","article-title":"An improved method for in vivo tracing and imaging liposomes using a (67)gallium-Deferoxamine complex","volume":"1","author":"Gabizon","year":"1988","journal-title":"J. Liposome Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0005-2736(91)90162-2","article-title":"Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times","volume":"1070","author":"Lasic","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"issue":"24","key":"10.1016\/j.jconrel.2025.113731_bb0165","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy","volume":"88","author":"Papahadjopoulos","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113731_bb0170","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1018907715905","article-title":"Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs","volume":"10","author":"Gabizon","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.113731_bb0175","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2016.11.014","article-title":"Tumor-targeted nanomedicines for cancer theranostics","volume":"115","author":"Arranja","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0180","doi-asserted-by":"crossref","first-page":"956","DOI":"10.7150\/thno.38288","article-title":"Imaging-assisted anticancer nanotherapy","volume":"10","author":"Dasgupta","year":"2020","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0185","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0190","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1039\/c2ib20174g","article-title":"Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions","volume":"5","author":"Bradbury","year":"2013","journal-title":"Integr. Biol. (Camb)."},{"key":"10.1016\/j.jconrel.2025.113731_bb0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estap\u00e9 Senti","year":"2022","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0200","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0205","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acsnano.0c03648","article-title":"Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines","volume":"14","author":"Gabizon","year":"2020","journal-title":"ACS Nano"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2025.113731_bb0210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.09.047","article-title":"Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin","volume":"476","author":"Suzuki","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0220","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejps.2011.09.006","article-title":"Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy","volume":"45","author":"Gabizon","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113731_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113588","article-title":"TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65\/16)","volume":"201","author":"Colombo","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0230","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-024-04679-z","article-title":"Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial","volume":"94","author":"Mc Laughlin","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2013.02.003","article-title":"Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity","volume":"167","author":"Shmeeda","year":"2013","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0240","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0245","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0009-9236(97)90162-4","article-title":"Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi\u2019s sarcoma","volume":"61","author":"Amantea","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0250","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man","volume":"50","author":"Freireich","year":"1966","journal-title":"Cancer Chemother. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113731_bb0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1010639201787","article-title":"Body surface area as a determinant of pharmacokinetics and drug dosing","volume":"19","author":"Sawyer","year":"2001","journal-title":"Investig. New Drugs"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113731_bb0260","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113731_bb0265","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jconrel.2021.04.028","article-title":"(poly-cyanoacrylate) nanomedicines for cancer and beyond: lessons learned","volume":"334","author":"Couvreur","year":"2021","journal-title":"J. Control. Release"},{"issue":"22","key":"10.1016\/j.jconrel.2025.113731_bb0270","doi-asserted-by":"crossref","first-page":"13983","DOI":"10.1021\/acsnano.4c00182","article-title":"Mechanisms and barriers in nanomedicine: Progress in the field and future directions","volume":"18","author":"Anchordoquy","year":"2024","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113731_bb0275","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113731_bb0280","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113731_bb0285","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1081\/CNV-200032899","article-title":"Cardiac safety of pegylated liposomal doxorubicin (Doxil\/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies","volume":"22","author":"Gabizon","year":"2004","journal-title":"Cancer Investig."},{"issue":"18","key":"10.1016\/j.jconrel.2025.113731_bb0290","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113731_bb0295","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bioactmat.2022.12.027","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioactive Mater."},{"key":"10.1016\/j.jconrel.2025.113731_bb0300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2015.04.009","article-title":"A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index","volume":"208","author":"Scomparin","year":"2015","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-009-1132-4","article-title":"Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models","volume":"66","author":"Gabizon","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113731_bb0310","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.2147\/IJN.S182579","article-title":"Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts","volume":"13","author":"Christensen","year":"2018","journal-title":"Int. J. Nanomedicine"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113731_bb0315","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","article-title":"Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models","volume":"17","author":"Rios-Doria","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2025.113731_bb0320","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jconrel.2024.07.045","article-title":"Nano-mupirocin as tumor-targeted antibiotic: physicochemical, immunotoxicological and pharmacokinetic characterization, and effect on gut microbiome","volume":"373","author":"Cern","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113731_bb0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2020.07.027","article-title":"Development of Promitil(R), a lipidic prodrug of mitomycin c in PEGylated liposomes: from bench to bedside","volume":"154-155","author":"Gabizon","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113731_bb0330","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s10637-020-00897-3","article-title":"Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients","volume":"38","author":"Gabizon","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113731_bb0335","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-05-1547","article-title":"Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes","volume":"12","author":"Gabizon","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113731_bb0345","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00001813-199911000-00007","article-title":"Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models","volume":"10","author":"Bandak","year":"1999","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0350","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1023\/A:1011199028318","article-title":"Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer","volume":"12","author":"Harrington","year":"2001","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113731_bb0355","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0360","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2023.03.046","article-title":"Pegylated liposomal Mitomycin C Lipidic prodrug in combination with external beam radiation therapy in patients with advanced Cancer: a phase 1B study","volume":"117","author":"Sapir","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2025.113731_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116586","article-title":"Advances in liposomes loaded with photoresponse materials for cancer therapy","volume":"174","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2025.113731_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114503","article-title":"Temperature-sensitive polymers to promote heat-triggered drug release from liposomes: towards bypassing EPR","volume":"189","author":"Amin","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0375","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chemphyslip.2011.12.002","article-title":"Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation","volume":"165","author":"Ahmed","year":"2012","journal-title":"Chem. Phys. Lipids"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.apsb.2022.07.011","article-title":"Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy","volume":"13","author":"Butowska","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0385","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s12274-019-2308-9","article-title":"Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer","volume":"12","author":"Zhang","year":"2019","journal-title":"Nano Res."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0390","article-title":"Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy","volume":"5","author":"Mpekris","year":"2024","journal-title":"Cell Rep Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0395","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113731_bb0400","first-page":"463","article-title":"Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy","volume":"4","author":"Gabizon","year":"2021","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1871520618666180420170124","article-title":"Liposomes co- encapsulating anticancer drugs in synergistic ratios as an approach to promote increased efficacy and greater safety","volume":"19","author":"Franco","year":"2019","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"50","key":"10.1016\/j.jconrel.2025.113731_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr4762","article-title":"Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers","volume":"10","author":"Koshrovski-Michael","year":"2024","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113731_bb0415","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/pharmaceutics15112606","article-title":"Harnessing nanomedicine to potentiate the chemo-immunotherapeutic effects of doxorubicin and alendronate co-encapsulated in Pegylated liposomes","volume":"15","author":"Gabizon","year":"2023","journal-title":"Pharmaceutics"},{"issue":"26","key":"10.1016\/j.jconrel.2025.113731_bb0420","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113731_bb0425","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-23-0772","article-title":"Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas","volume":"23","author":"Charalambous","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0430","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113731_bb0435","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by Chemoradiotherapy for locally advanced pancreatic Cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113731_bb0440","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/1061186X.2016.1191081","article-title":"Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer","volume":"24","author":"Shmeeda","year":"2016","journal-title":"J. Drug Target."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113731_bb0445","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/ntno.75045","article-title":"Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model","volume":"6","author":"Islam","year":"2022","journal-title":"Nanotheranostics"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113731_bb0450","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/biom13091309","article-title":"Pegylated liposomal alendronate biodistribution, immune modulation, and tumor growth inhibition in a murine melanoma model","volume":"13","author":"Islam","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2025.113731_bb0455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2017.12.023","article-title":"Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate","volume":"271","author":"Rajan","year":"2018","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.jconrel.2025.113731_bb0460","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"(64)cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast Cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113731_bb0465","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41551-024-01197-4","article-title":"Histopathological biomarkers for predicting the tumour accumulation of nanomedicines","volume":"8","author":"May","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113731_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100990","article-title":"Adjuvant antitumor immunity contributes to the overall antitumor effect of Pegylated liposomal doxorubicin (Doxil(\u00ae)) in C26 tumor-bearing immunocompetent mice","volume":"12","author":"Takayama","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113731_bb0475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-030-17864-2_3","article-title":"HLA class-I expression and Cancer immunotherapy","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113731_bb0480","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","article-title":"Defective HLA class I antigen processing machinery in cancer","volume":"67","author":"Cai","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"13","key":"10.1016\/j.jconrel.2025.113731_bb0485","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/0008-5472.CAN-05-4199","article-title":"Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models","volume":"66","author":"Kirpotin","year":"2006","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113731_bb0490","doi-asserted-by":"crossref","first-page":"12015","DOI":"10.1021\/acsnano.8b04338","article-title":"Quantitative imaging of tumor-associated macrophages and their response to therapy using (64)cu-labeled Macrin","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113731_bb0495","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/imt-2016-0139","article-title":"Prospects for immunotherapy of acute myeloid leukemia using \u03b3\u03b4 T cells","volume":"9","author":"Halim","year":"2017","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113731_bb0500","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.4049\/jimmunol.1402200","article-title":"Adoptive immunotherapy of epithelial ovarian cancer with Vgamma9Vdelta2 T cells, potentiated by liposomal alendronic acid","volume":"193","author":"Parente-Pereira","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2025.113731_bb0505","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semcancer.2019.12.001","article-title":"Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment","volume":"68","author":"La-Beck","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113731_bb0510","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jconrel.2025.113731_bb0515","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2021.39.15_suppl.1049","article-title":"A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer","volume":"39","author":"Gabizon","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8049","key":"10.1016\/j.jconrel.2025.113731_bb0520","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41586-024-08439-0","article-title":"Immune evasion through mitochondrial transfer in the tumour microenvironment","volume":"638","author":"Ikeda","year":"2025","journal-title":"Nature"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:02:44Z","timestamp":1777870964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":104,"alternative-id":["S0168365925003517"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113731","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer nanomedicine from a clinician-scientist perspective: Lessons and prospects","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113731"}}